Ablative radiotherapy in castration-resistant prostate cancer.

BJU IntJul 2, 2026 (epub)
Clinical ResearchOncology (Medical)Urology

Tobias Hölscher, Fabian Lohaus, Lydia Koi et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized phase II trial evaluated the efficacy of metastasis-directed therapy (MDT) in patients with castration-resistant prostate cancer (CRPC) and up to five metastases. The study found that PSA progression within one year occurred in 44% of the MDT group compared to 75% in the observation group, with a median time to PSA progression of 12.4 months for MDT versus 2.9 months for observation.

Key findings

  • PSA progression within 1 year was 44% in the MDT group vs 75% in the OBS group (P = 0.14).
  • The median time to PSA progression was significantly longer in the MDT arm at 12.4 months compared to 2.9 months in the OBS arm (P = 0.03).

Why it matters

The findings suggest that metastasis-directed therapy may prolong the time to PSA progression in patients with oligometastatic CRPC, which could influence treatment strategies in this population.

What to keep in mind

The study's limitations include its single-centre design and small sample size at the interim analysis.

Source

PubMed · PMID 42389925

Published in BJU Int. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.